parties; future
capital needs; and risks relating to the commercialization, if any, of the
Company's proposed products (such as marketing, safety, regulatory, patent,
product liability, supply, competition and other risks).
CONTACT:
Ginny Dunn
EntreMed, Inc.
Associate Director
Corporate Communications &
Investor Relations
240-864-2643
ENTREMED, INC.
SUMMARY OF OPERATING RESULTS
Three Months Ended
September 30,
2007 2006
Total revenues $3,520,259 $3,023,185
Research and development 5,109,257 5,544,134
General and administrative 1,706,451 1,497,612
Acquired in-process research and
development 0 0
Net Loss (3,035,346) (3,524,998)
Net Loss per share (basic and diluted)
attributable to common shareholders $(0.04) $(0.05)
Weighted average number of shares
outstanding (basic and diluted) 84,223,912 73,288,499
Nine Months Ended
September 30,
2007 2006
Total revenues $3,520,259 $3,023,185
Research and development 18,089,240 13,813,440
General and administrative 5,407,588 5,256,958
Acquired in-process research and
development 0 29,481,894
Net Loss (18,643,625) (44,261,425)
Net Loss per share (basic)
attributable to common share
'/>"/>
SOURCE EntreMed, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related medicine news :1.
EntreMed Receives Deloitte Technology Fast 50 Award2.
EntreMed to Present at the Bio 2007 Investor Forum3.
EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study4.
EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference5.
New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites6.
Haemacure Reports Third Quarter 2007 Results7.
First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion8.
Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best9.
MDS Reports Third Quarter 2007 Results10.
Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 200611.
AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System